Docetaxel

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21780 publications

Retraction notice to "Effects of the combination of RAD001 and docetaxel on breast cancer stem cells" [Eur J Cancer 48 (2012) 1581-1592].

Retraction notice to "Effects of the combination of RAD001 and docetaxel on breast cancer stem cells" [Eur J Cancer 48 (2012) 1581-1592].

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 15, 2026

METTL16 promotes taxane resistance in Triple-Negative Breast Cancer through m 6 A-dependent translational upregulation of ABCB1.

METTL16 promotes taxane resistance in Triple-Negative Breast Cancer through m 6 A-dependent translational upregulation of ABCB1.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage Cancer.

Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage Cancer.

Journal: JAMA network open

Published: April 10, 2026

Atypical Presentation of Grade III Hand-Foot Syndrome in a Patient With Breast Cancer Receiving Docetaxel.

Atypical Presentation of Grade III Hand-Foot Syndrome in a Patient With Breast Cancer Receiving Docetaxel.

Journal: American journal of therapeutics

Published: April 09, 2026

Response to comment on 'Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer'.

Response to comment on 'Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer'.

Journal: BJU international

Published: April 08, 2026

Comment on 'Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer'.

Comment on 'Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer'.

Journal: BJU international

Published: April 07, 2026

Mitochondrial protein translation is a heightened dependence and therapeutic vulnerability of chemo-refractory triple negative breast cancer.

Mitochondrial protein translation is a heightened dependence and therapeutic vulnerability of chemo-refractory triple negative breast cancer.

Journal: bioRxiv : the preprint server for biology

Published: April 03, 2026

Tumor cell membrane-camouflaged nanoparticles co-delivering docetaxel and metformin for enhanced synergistic therapy of HER2-positive breast cancer.

Tumor cell membrane-camouflaged nanoparticles co-delivering docetaxel and metformin for enhanced synergistic therapy of HER2-positive breast cancer.

Journal: Pharmaceutical development and technology

Published: March 31, 2026

A smart P-gp inhibitor-drug conjugate nanomedicine overcomes administration challenges and multidrug resistance in breast cancer therapy.

A smart P-gp inhibitor-drug conjugate nanomedicine overcomes administration challenges and multidrug resistance in breast cancer therapy.

Journal: Biomaterials science

Published: March 30, 2026

Retraction notice to "New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities" [Biomedicine & Pharmacotherapy 141 (2021) 111824].

Retraction notice to "New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities" [Biomedicine & Pharmacotherapy 141 (2021) 111824].

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: March 20, 2026

Retraction notice to "Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies" [Biomedicine & Pharmacotherapy 160 (2023) 114392].

Retraction notice to "Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies" [Biomedicine & Pharmacotherapy 160 (2023) 114392].

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: March 20, 2026

Alternate-day administration of intravesical gemcitabine and docetaxel to improve clinic utilisation.

Alternate-day administration of intravesical gemcitabine and docetaxel to improve clinic utilisation.

Journal: BJU international

Published: March 18, 2026

Showing 1-12 of 21,780

Last Updated: 04/28/2026